Researchers at Ural Federal University (UrFU) have proposed the use of polyoxometallate nanoclusters as a carrier for chemotherapy drug.

It will help to deliver medications precisely to the focus of a pathological process, such as a cancerous tumour, without toxic effects on healthy cells.

Delivery can be accomplished either by electrophoresis or by injection into the bloodstream. The development is described in the AIP Conference Proceedings.

“We've explored molybdenum polyoxometalates. It is polyatomic ions composed of molybdenum and iron, joined together by common oxygen atoms, containing organic groups. Their peculiarity is that they are a nanocluster to the surface of which a medication can be attached and delivered to the tumour formation. Polyoxometallates themselves are not toxic to living cells and do not change their function or morphology. On the contrary, cells are able to absorb these nanocapsules without any harm. Polyoxometallates give, in the body of warm-blooded animals, the effect of increasing the haemoglobin level and the number of red blood cells, which allows to use them for the treatment and prevention of anemia (the development is patented),” says Maria Ulitko, Director of the Faculty of Biology and Fundamental Medicine at the UrFU.

Futher scientists plan to attach a vector molecule to the surface of the polyoxometallate that can distinguish cancer cells and ensure binding of the nanocluster to them, bypassing healthy ones.

They tested how the nanocluster would interact with doxorubicin. This is a well-known anticancer antibiotic. It is good at destroying tumour structures, but has low selectivity.

High concentrations of the medication needed to destroy cancer cells are toxic to the weakened body. Scientists figured out how a polyoxometallate with an antibiotic inside would affect healthy and tumour cells and selected the most effective concentration of the medication.

“The undoubted advantage of targeted delivery is the possibility to adjust the medication dose. Our studies have shown that too high a concentration of doxorubicin in a polyoxometallate capsule will also lead to the death of healthy cells: the container will not be able to keep the active substances from getting into DNA through the nuclear and cell membranes,” explains Aleksandr Ostroushko, Head of the Section of Chemical Material Science at UrFU.

Now researchers are conducting on cell structures of cervical cancer (carcinoma). In the future, this method of delivery can also be applied to other tumours.

At the next stage of the work, scientists plan to conduct preclinical studies on laboratory animals to evaluate the therapeutic efficacy and safety of the system.

The authors note that nanocluster compounds will be able to deliver other medications, such as anti-inflammatory ones. The developed technology will help to improve the accuracy of targeted delivery of medications with strong side effects.

Source: Ural Federal University